50 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
29 Jul 19
Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results
4:40pm
equivalents and short-term investments will enable it to fund its operations into the fourth quarter of 2020.
· R&D Expenses: R&D expenses were $35.3 … drivers of the R&D increase were: an increase of $4.6 million related to translational research and genetic sequencing efforts designed to improve
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am
candidate for the treatment of CHI and provide updates on early-stage R&D efforts in the fourth quarter of 2023; and
Complete patient enrollment … for the first quarter of 2022. For the first quarter ended March 31, 2023, 83% of the Company’s product revenue was generated in the United States.
R&D Expenses
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
to provide update on R&D programs for investors and analysts at an event planned for Dec. 6 --
-- Management to host conference call today at 8:00 a.m … Phase 3 study reinforce our confidence as we advance this high potential program. We look forward to providing an R&D update, including our RM-718
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
2 Nov 20
Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results
9:32am
it to fund its operations at least through the end of 2021.
R&D Expenses: R&D expenses were $23.0 million for the third quarter of 2020 as compared to $26.6 … million for the third quarter of 2019. The decrease in R&D spending was primarily attributed to a $5.2 million reduction in clinical trial expenses
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
3 May 19
Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results
5:08pm
half of 2020.
· R&D Expenses: R&D expenses were $22.8 million for the first quarter of 2019 as compared to $12.3 million for the first quarter … syndrome. Additional drivers of the R&D increase were: an increase of $2.5 million in employee-related costs due to the hiring of additional personnel
8-K
EX-99.1
lff1g0yh4o8ahjex
3 Aug 20
Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results
9:25am
8-K
EX-99.1
0bwcq
25 Sep 19
Rhythm Pharmaceuticals Provides Update on Research and Development Programs
8:30am
8-K
EX-99.1
thoiootqgvyl
1 Nov 19
Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results
4:22pm
8-K
EX-99.1
f2q1fguebtt 8po5yqg7
3 Aug 21
Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
4nonl 9vvonirjsyp6f
2 Aug 22
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
7:02am
8-K
EX-99.1
xflgw5l0
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
z5kyt0bmejqsl9hnbq55
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
8-K
EX-99.1
8espto 4v0
8 Nov 22
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
7:03am
8-K
EX-99.1
kkwfq4qr wbssfc2r3lq
7 May 24
Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
7:10am
8-K
EX-99.1
74s7tcrreijksk5d2
2 Nov 21
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
v62g8lhnrfsyj
9 Aug 18
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results
4:07pm
8-K
EX-99.1
dycl14hriy
3 May 22
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
7:05am
8-K
EX-99.1
z24evo6xgx29a
14 May 18
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results
4:01pm
8-K
EX-99.1
0fzx gxvl
2 Mar 20
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
4:51pm
8-K
EX-99.1
z4xwzd5
3 May 21
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
8:54am